Kemwell Biopharma increases biologics manufacturing capacity

As part of this expansion, the company has installed Ambr 250, high throughput equipment

Kemwell Biopharma, a biologics contract development and manufacturing service provider, has recently augmented its existing infrastructure. As part of this expansion, the company has installed Ambr 250, high throughput equipment with 12 automated mini bioreactors at a 250 ml scale to accelerate process development.

Ambr 250 enables setting of 12 different media conditions, temperatures and gases, helping the client projects identify optimal processes for higher titers while reducing the cost per experiment. In addition to Ambr 250, 3 more 5 L scale glass bioreactors are installed and the facility now houses a total of 12 bioreactors of 5 and 10 L scale.

The company is also expanding its manufacturing capacity further by adding three single-use bioreactors (SUBs) this month. It plans to install 100, 200 and 1000 L SUBs in its existing CGMP plant to support process scale-up and preclinical toxicology batch and early clinical trial supplies, which are aimed to be operational by October 2021.

With the above addition, Kemwell will have 5000 L of cGMP manufacturing capacity and has a further investment plan to install an additional 12,000 L of bioreactor capacity in an existing shell space of 26,000 sq ft for an investment of $25 m. The company is exploring strategic partnerships with biopharma players in the ecosystem to fit out this additional capacity which can be executed within 12-15 months.